WallStSmart

Mainz Biomed BV (MYNZ)vsNovartis AG ADR (NVS)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 8692206% more annual revenue ($57.36B vs $659,940). NVS leads profitability with a 17.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 48/100 (D+).

MYNZ

Avoid

18

out of 100

Grade: F

Growth: 4.7Profit: 2.5Value: 5.0Quality: 4.0
Piotroski: 6/9Altman Z: -14.01

NVS

Hold

48

out of 100

Grade: D+

Growth: 4.0Profit: 9.0Value: 2.7Quality: 5.5
Piotroski: 6/9Altman Z: 2.06
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for MYNZ.

NVSSignificantly Overvalued (-56.8%)

Margin of Safety

-56.8%

Fair Value

$95.95

Current Price

$150.47

$54.52 premium

UndervaluedFair: $95.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MYNZ1 strengths · Avg: 10.0/10
Price/BookValuation
0.8x10/10

Reasonable price relative to book value

NVS4 strengths · Avg: 9.3/10
Market CapQuality
$302.86B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
34.0%10/10

Strong operational efficiency at 34.0%

Return on EquityProfitability
26.9%9/10

Every $100 of equity generates 27 in profit

Free Cash FlowQuality
$4.76B8/10

Generating 4.8B in free cash flow

Areas to Watch

MYNZ4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$7.90M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Debt/EquityHealth
1.233/10

Elevated debt levels

NVS4 concerns · Avg: 3.3/10
P/E RatioValuation
30.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Debt/EquityHealth
1.303/10

Elevated debt levels

PEG RatioValuation
3.812/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : MYNZ

The strongest argument for MYNZ centers on Price/Book.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.0%.

Bear Case : MYNZ

The primary concerns for MYNZ are EPS Growth, Market Cap, Profit Margin.

Bear Case : NVS

The primary concerns for NVS are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

NVS carries more volatility with a beta of 0.45 — expect wider price swings.

NVS is growing revenue faster at 4.7% — sustainability is the question.

NVS generates stronger free cash flow (4.8B), providing more financial flexibility.

Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NVS scores higher overall (48/100 vs 18/100), backed by strong 17.5% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Mainz Biomed BV

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Mainz Biomed BV is an innovative biotechnology company specializing in the development of advanced diagnostic solutions for early cancer detection, with a particular emphasis on gastrointestinal disorders. The company's flagship product, a proprietary non-invasive colorectal cancer screening test, employs state-of-the-art biomarker technology to improve the accuracy and accessibility of screenings. As a key player in the rapidly expanding diagnostics market, Mainz Biomed is dedicated to meeting critical clinical needs and enhancing patient outcomes. With a strong intellectual property position and a focus on research and development, the company is poised to capitalize on the increasing global demand for effective cancer diagnostic tools.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?